# A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance

Source: https://onco.cc/trials/nct04810078/  
OnCo record `nct04810078` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Nivolumab in renal cell carcinoma, run by Bristol-Myers Squibb, active and no longer recruiting.

## Summary

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread is a phase 3 interventional study registered as NCT04810078 by Bristol-Myers Squibb, with 681 participants enrolled, started 2021-05-21 and due to reach its primary completion in 2025-07-29. Interventions recorded: Nivolumab and rHuPH20, Nivolumab. Conditions listed: Clear Cell Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04810078
- Phase: 3
- Setting: A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy
- Sponsor: Bristol-Myers Squibb
- Enrolled: 681

## Sources

- ClinicalTrials.gov NCT04810078: https://clinicaltrials.gov/study/NCT04810078

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct04810078.json